---
trial_id: 554
discovery_date: 2022-04-10 16:23:54.540109
date: 2022-04-10 16:23:54.540109
title: "Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)"
summary: |
  <p>EudraCT Number: 2017-000638-75<br />Sponsor Protocol Number: TG1101-RMS301<br />Sponsor Name: TG Therapeutics<br />Start Date: 2017-12-05<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029202<br />Term: Nervous system disorder<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/PL">PL</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/ES">ES</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000638-75'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2017-000638-75<br />Sponsor Protocol Number: TG1101-RMS301<br />Sponsor Name: TG Therapeutics<br />Start Date: 2017-12-05<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029202<br />Term: Nervous system disorder<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/PL">PL</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/ES">ES</a> (Completed)</p>